^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IMA101
i
Other names: IMA101, IMA101 T cells, ACTolog IMA101
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Immatics
Drug class:
TCR modulator
Related drugs:
11ms
Autologous engineered T cell receptor therapy in advanced cancer. (PubMed, Hum Vaccin Immunother)
Of 214 screened patients, 14 were treated (6, IMA101; 8, IMA101 and atezolizumab). Target-specific T cells expanded to constitute up to 78.7% of CD8+ cells. In conclusion, IMA101 was feasible and well tolerated, leveraging the potential of multi-targeted ACT that warrants further investigation.
Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • IL2 (Interleukin 2) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • COL6A3 (Collagen Type VI Alpha 3 Chain) • MMP1 (Matrix metallopeptidase 1) • MAGEA1 (MAGE Family Member A1)
|
PRAME expression
|
Tecentriq (atezolizumab) • IMA101
over1year
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer. (PubMed, Cancer Immunol Res)
Patients received lymphodepletion (fludarabine, cyclophosphamide), followed by T-cell infusion and low-dose IL2 (Cohort 1). Patients in Cohort 2 received atezolizumab for up to 1 year (NCT02876510)...This study demonstrates the feasibility and tolerability of an actively personalized ACT directed to multiple defined pHLA cancer targets. Results warrant further evaluation of multi-target ACT approaches using potent high-avidity TCRs.
P1 data • Journal • Metastases
|
CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02:01 • HLA-A*02
|
Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • IMA101
Share via
